{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:44:02Z","timestamp":1787694242672,"version":"build-2784847793"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.metabol.2021.154887","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:47:43Z","timestamp":1631105263000},"page":"154887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Unravelling lipoprotein metabolism with stable isotopes: tracing the flow"],"prefix":"10.1016","volume":"124","author":[{"given":"Qidi","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Hugh R.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154887_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154887_bb0010","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154887_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2021.154887_bb0020","doi-asserted-by":"crossref","unstructured":"Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:34\u201342 contd.","DOI":"10.1056\/NEJM196701052760107"},{"key":"10.1016\/j.metabol.2021.154887_bb0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1042\/CS20040108","article-title":"Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies","volume":"107","author":"Chan","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0030","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1194\/jlr.R600017-JLR200","article-title":"Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans","volume":"47","author":"Barrett","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1194\/jlr.M400108-JLR200","article-title":"A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions","volume":"46","author":"Adiels","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0040","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0045","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, S\u00f6derlund S, et al. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. J Intern Med. 2019;;285:562\u201377.","DOI":"10.1111\/joim.12877"},{"key":"10.1016\/j.metabol.2021.154887_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.108.178756","article-title":"Triglyceride-rich lipoproteins and plasma lipid transport","volume":"30","author":"Havel","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0055","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/01.CIR.82.5.1574","article-title":"Recent progress in understanding apolipoprotein B","volume":"82","author":"Young","year":"1990","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0060","series-title":"Rosales C","author":"Pownall","year":"2021"},{"key":"10.1016\/j.metabol.2021.154887_bb0065","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0022-2275(20)42353-3","article-title":"Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics","volume":"31","author":"Lichtenstein","year":"1990","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0026-0495(97)90262-6","article-title":"The 3H-leucine tracer: its use in kinetics studies of plasma lipoproteins","volume":"46","author":"Fisher","year":"1997","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0080","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2337\/diabetes.51.8.2377","article-title":"Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia","volume":"51","author":"Chan","year":"2002","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154887_bb0085","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1210\/jc.2019-01382","article-title":"Apolipoprotein(a) kinetics in statin-treated patients with elevated plasma lipoprotein(a) concentration","volume":"104","author":"Ma","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0090","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","article-title":"Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome","volume":"52","author":"Watts","year":"2003","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154887_bb0095","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154887_bb0100","doi-asserted-by":"crossref","first-page":"154221","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0105","doi-asserted-by":"crossref","first-page":"E1427","DOI":"10.1210\/jc.2013-4037","article-title":"Effect of \u03c9-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state","volume":"99","author":"Wong","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/ATVBAHA.120.315446","article-title":"Effects of evolocumab on the postprandial kinetics of apo (apolipoprotein) B100- and B48-containing lipoproteins in subjects with type 2 diabetes","volume":"41","author":"Taskinen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1194\/jlr.D064618","article-title":"Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC\/MS\/MS","volume":"57","author":"Croyal","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0120","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.metabol.2008.03.011","article-title":"Using mass measurements in tracer studies-a systematic approach to efficient modeling","volume":"57","author":"Ramakrishnan","year":"2008","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0125","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0026-0495(98)90064-6","article-title":"SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies","volume":"47","author":"Barrett","year":"1998","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0130","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-90a."},{"key":"10.1016\/j.metabol.2021.154887_bb0135","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.metabol.2021.154887_bb0140","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.jlr.2021.100062","article-title":"Lipoprotein metabolism in familial hypercholesterolemia","volume":"62","author":"Chemello","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11886-017-0848-8","article-title":"Genetic architecture of familial hypercholesterolaemia","volume":"19","author":"Sharifi","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.metabol.2021.154887_bb0150","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1194\/jlr.TR120001001","article-title":"FH through the retrospectoscope","volume":"62","author":"Thompson","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI109490","article-title":"Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo","volume":"64","author":"Bilheimer","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0160","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0026-0495(76)90129-3","article-title":"Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients","volume":"25","author":"Packard","year":"1976","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0165","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1194\/jlr.M300448-JLR200","article-title":"Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation","volume":"45","author":"Tremblay","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0170","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/ATVBAHA.119.313877","article-title":"VLDL (very-low-density lipoprotein)-Apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly","volume":"40","author":"Croyal","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0021-9150(94)05430-Q","article-title":"Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study","volume":"113","author":"Cummings","year":"1995","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154887_bb0180","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","article-title":"Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production","volume":"25","author":"Millar","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0185","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-2275(20)37589-1","article-title":"Role of cholesterol in regulating apolipoprotein B secretion by the liver","volume":"37","author":"Thompson","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2011.07.014","article-title":"Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box","volume":"61","author":"Chan","year":"2012","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0200","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ijcard.2013.06.069","article-title":"The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies","volume":"168","author":"Ooi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0205","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1210\/jc.2016-2217","article-title":"Omega-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia","volume":"101","author":"Chan","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0210","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-2275(20)33394-0","article-title":"Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study","volume":"40","author":"Fr\u00e9nais","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0215","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.ATV.12.7.843","article-title":"In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia","volume":"12","author":"Schaefer","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.metabol.2021.154887_bb0220","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/01.ATV.20.7.1796","article-title":"Increased production of HDL ApoA-I in homozygous familial defective ApoB-100","volume":"20","author":"Schaefer","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-5793(89)80132-2","article-title":"Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A-I mRNA in Hep G2 cells","volume":"243","author":"Monge","year":"1989","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2021.154887_bb0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science."},{"key":"10.1016\/j.metabol.2021.154887_bb0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2362.1995.tb01746.x","article-title":"Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications","volume":"25","author":"Watts","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0245","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0250","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0255","doi-asserted-by":"crossref","first-page":"104653","DOI":"10.1016\/j.phrs.2020.104653","article-title":"Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia","volume":"153","author":"Ruscica","year":"2020","journal-title":"Pharmacol Res"},{"issue":"Suppl","key":"10.1016\/j.metabol.2021.154887_bb0260","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0265","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0270","doi-asserted-by":"crossref","first-page":"603910","DOI":"10.3389\/fphys.2021.603910","article-title":"New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects","volume":"12","author":"Ying","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0275","doi-asserted-by":"crossref","unstructured":"Ferri N, Grego MF, Corsini A, Ruscica M. Proprotein convertase subtilisin\/kexin type 9: an update on the cardiovascular outcome studies. Eur Heart J Suppl 2020;22:E64-E7.","DOI":"10.1093\/eurheartj\/suaa063"},{"key":"10.1016\/j.metabol.2021.154887_bb0280","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0285","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0290","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOL.0000000000000747","article-title":"Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management","volume":"32","author":"Ying","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2021.154887_bb0295","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2021.154887_bb0300","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine."},{"key":"10.1016\/j.metabol.2021.154887_bb0305","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase*","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154887_bb0310","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0315","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0320","doi-asserted-by":"crossref","unstructured":"Reeskamp Laurens F, Millar John S, Wu L, Jansen H, van Harskamp D, Schierbeek H, et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021;0:ATVBAHA.120.315204.","DOI":"10.1161\/ATVBAHA.120.315204"},{"key":"10.1016\/j.metabol.2021.154887_bb0325","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0330","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.plipres.2017.09.001","article-title":"The renaissance of lipoprotein(a): brave new world for preventive cardiology?","volume":"68","author":"Ellis","year":"2017","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb4000","doi-asserted-by":"crossref","first-page":"e0117814","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2021.154887_bb0340","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.metabol.2019.04.010","article-title":"Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration","volume":"96","author":"Ma","year":"2019","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0345","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1161\/ATVBAHA.115.306136","article-title":"Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus","volume":"35","author":"Ooi","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0350","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0355","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0360","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","article-title":"Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431239 patients","volume":"37","author":"Moriarty","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0365","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jc.2017-01049","article-title":"Effect of APOE \u03b5 genotype on lipoprotein(a) and the associated risk of myocardial infarction and aortic valve stenosis","volume":"102","author":"Kritharides","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0370","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1194\/jlr.P083576","article-title":"Kinetics of plasma apolipoprotein E isoforms by LC-MS\/MS: a pilot study","volume":"59","author":"Blanchard","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0375","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0380","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0385","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0390","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.metabol.2021.154887_bb0395","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20160403","article-title":"The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies","volume":"131","author":"Lambert","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0400","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0405","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0410","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0415","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0420","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154887_bb0425","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154887_bb0430","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2021.154887_bb0435","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.ijo.0800602","article-title":"Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity","volume":"22","author":"Riches","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.metabol.2021.154887_bb0440","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/meta.2002.33339","article-title":"Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration","volume":"51","author":"Chan","year":"2002","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0445","doi-asserted-by":"crossref","unstructured":"Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naoumova R, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin Sci (Lond). 1995;88:225\u201333.","DOI":"10.1042\/cs0880225"},{"key":"10.1016\/j.metabol.2021.154887_bb0450","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1042\/cs1010683","article-title":"Preliminary experience with a new stable isotope breath test for chylomicron remnant metabolism: a study in central obesity","volume":"101","author":"Watts","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0455","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.clinbiochem.2005.05.009","article-title":"Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men","volume":"38","author":"Chan","year":"2005","journal-title":"Clin Biochem"},{"key":"10.1016\/j.metabol.2021.154887_bb0460","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/oby.2003.24","article-title":"Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men","volume":"11","author":"Watts","year":"2003","journal-title":"Obes Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0465","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/01.ATV.0000172689.53992.25","article-title":"Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia","volume":"25","author":"Adiels","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0470","doi-asserted-by":"crossref","unstructured":"Packard CJ, Boren J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:252.","DOI":"10.3389\/fendo.2020.00252"},{"key":"10.1016\/j.metabol.2021.154887_bb0475","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0480","first-page":"685","article-title":"Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study","volume":"30","author":"Duvillard","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0485","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/ATVBAHA.115.305614","article-title":"Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study","volume":"35","author":"Bor\u00e9n","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOL.0b013e3283378e5a","article-title":"Genetic determinants of apolipoprotein B-100 kinetics","volume":"21","author":"Ng","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2021.154887_bb0495","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S0022-2275(20)32162-3","article-title":"Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men","volume":"39","author":"Riches","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0500","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-2275(20)34487-4","article-title":"Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity","volume":"41","author":"Watts","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0505","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/01.ATV.0000143532.93729.d6","article-title":"ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men","volume":"24","author":"Chan","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0510","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144079","article-title":"Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans","volume":"5","author":"Bor\u00e9n","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.metabol.2021.154887_bb0515","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1210\/jc.2013-2477","article-title":"Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state","volume":"99","author":"Wong","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0520","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/dom.12622","article-title":"Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes","volume":"18","author":"Pang","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0525","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1742-1241.2007.01678.x","article-title":"An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?","volume":"62","author":"Chan","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2021.154887_bb0530","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.13744","article-title":"Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia","volume":"21","author":"Adiels","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0535","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020;11:474.","DOI":"10.3389\/fendo.2020.00474"},{"key":"10.1016\/j.metabol.2021.154887_bb0540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0545","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2006-2676","article-title":"Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism","volume":"93","author":"Chan","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0550","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/eci.12657","article-title":"Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III","volume":"46","author":"Ooi","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0555","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2004.06.011","article-title":"Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia","volume":"177","author":"Cohn","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154887_bb0560","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/CS20140559","article-title":"Inter-relationships between proprotein convertase subtilisin\/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state","volume":"128","author":"Chan","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0565","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154887_bb0570","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/oby.2005.118","article-title":"High-density lipoprotein apolipoprotein A-I kinetics in obesity","volume":"13","author":"Ooi","year":"2005","journal-title":"Obes Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0575","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.ijo.0802070","article-title":"High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study","volume":"26","author":"Pont","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.metabol.2021.154887_bb0580","first-page":"2854","article-title":"Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men","volume":"84","author":"Riches","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0585","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc07-0768","article-title":"Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels","volume":"30","author":"Ng","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154887_bb0590","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0595","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fcvm.2019.00069","article-title":"Effects of exercise to improve cardiovascular health","volume":"6","author":"Pinckard","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0600","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1152\/ajpendo.00408.2002","article-title":"Blood flow and muscle metabolism: a focus on insulin action","volume":"284","author":"Clark","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0605","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/diabetes.50.5.921","article-title":"AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise","volume":"50","author":"Musi","year":"2001","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154887_bb0610","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/db06-1119","article-title":"Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study","volume":"56","author":"Sriwijitkamol","year":"2007","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154887_bb0615","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/jc.2003-031036","article-title":"The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes","volume":"89","author":"Alam","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0620","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1210\/jc.2016-2353","article-title":"Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD","volume":"101","author":"Shojaee-Moradie","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0625","doi-asserted-by":"crossref","unstructured":"Whyte MB, Shojaee-Moradie F, Sharaf SE, Cuthbertson DJ, Kemp GJ, Barrett M, et al. HDL-apoA-I kinetics in response to 16 wk of exercise training in men with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2020;318:E839-E47.","DOI":"10.1152\/ajpendo.00019.2020"},{"key":"10.1016\/j.metabol.2021.154887_bb0630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0635","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00041433-200002000-00002","article-title":"Omega-3 polyunsaturated fatty acid regulation of gene expression","volume":"11","author":"Price","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2021.154887_bb0640","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.ATV.12.6.691","article-title":"Apolipoprotein B mRNA abundance is decreased by eicosapentaenoic acid in CaCo-2 cells. Effect on the synthesis and secretion of apolipoprotein B","volume":"12","author":"Murthy","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.metabol.2021.154887_bb0645","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-2275(20)37255-2","article-title":"Changes in fatty acid metabolism in rat hepatocytes in response to dietary n-3 fatty acids are associated with changes in the intracellular metabolism and secretion of apolipoprotein B-48","volume":"38","author":"Brown","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0650","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00125-006-0315-3","article-title":"Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids","volume":"49","author":"Levy","year":"2006","journal-title":"Diabetologia."},{"key":"10.1016\/j.metabol.2021.154887_bb0655","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","article-title":"Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity","volume":"77","author":"Chan","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2021.154887_bb0660","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20120587","article-title":"Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men","volume":"125","author":"Wong","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154887_bb0665","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3945\/ajcn.2009.28422","article-title":"Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity","volume":"91","author":"Chan","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2021.154887_bb0670","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ajcn\/84.1.37","article-title":"Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity","volume":"84","author":"Chan","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2021.154887_bb0675","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9150(00)00723-1","article-title":"Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus","volume":"157","author":"Fr\u00e9nais","year":"2001","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154887_bb0680","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/jc.2005-2084","article-title":"REVIEW: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia","volume":"91","author":"Ginsberg","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0685","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2014-4348","article-title":"Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment","volume":"100","author":"Ng","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0690","doi-asserted-by":"crossref","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","article-title":"Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome","volume":"99","author":"Ng","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0695","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1210\/jcem.87.5.8455","article-title":"Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity","volume":"87","author":"Chan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0700","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.ijo.0802287","article-title":"Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome","volume":"27","author":"Watts","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.metabol.2021.154887_bb0705","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2007.03.004","article-title":"Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome","volume":"197","author":"Ooi","year":"2008","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154887_bb0710","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00052-7","article-title":"Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates","volume":"164","author":"Forster","year":"2002","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154887_bb0715","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1194\/jlr.M300309-JLR200","article-title":"Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia","volume":"45","author":"Bilz","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0720","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1194\/jlr.M500335-JLR200","article-title":"Tretment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia","volume":"46","author":"Myerson","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0725","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc08-0358","article-title":"Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome","volume":"31","author":"Ooi","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154887_bb0730","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1194\/jlr.P900003-JLR200","article-title":"Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III","volume":"50","author":"Chan","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0735","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1194\/jlr.P029223","article-title":"Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome","volume":"53","author":"Ooi","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0740","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1194\/jlr.P800040-JLR200","article-title":"Pais de Barros JP, et al. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes","volume":"50","author":"Verg\u00e8s","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0745","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2007-0854","article-title":"Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome","volume":"93","author":"Ooi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0750","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0755","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors","volume":"14","author":"Repa","year":"2000","journal-title":"LXRalpha and LXRbeta Genes Dev"},{"key":"10.1016\/j.metabol.2021.154887_bb0760","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2021.154887_bb0765","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/ATVBAHA.108.170530","article-title":"Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome","volume":"28","author":"Chan","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0770","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.metabol.2007.09.008","article-title":"Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia","volume":"57","author":"Hogue","year":"2008","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154887_bb0775","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","article-title":"Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"115","author":"Nagashima","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154887_bb0780","doi-asserted-by":"crossref","first-page":"E1568","DOI":"10.1210\/jc.2011-1131","article-title":"Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity","volume":"96","author":"Ooi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0785","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0790","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0795","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland a, et al. Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/kexin type 9 expression","volume":"44","author":"Verg\u00e8s","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154887_bb0800","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2021.154887_bb0805","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/dom.13257","article-title":"Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial","volume":"20","author":"Ray","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154887_bb0810","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-0991-1","article-title":"Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol","volume":"19","author":"Colhoun","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2021.154887_bb0815","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacl.2019.12.003","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects","volume":"14","author":"Taskinen","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2021.154887_bb0820","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154887_bb0825","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/01.ATV.0000219695.84644.56","article-title":"Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans","volume":"26","author":"Millar","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0830","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0835","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1194\/jlr.P800037-JLR200","article-title":"Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism","volume":"50","author":"Brousseau","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0840","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/ATVBAHA.115.306680","article-title":"Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein","volume":"36","author":"Reyes-Soffer","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0845","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154887_bb0850","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0855","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154887_bb0860","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2021.154887_bb0865","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11883-010-0100-0","article-title":"Lipidomics as a tool for the study of lipoprotein metabolism","volume":"12","author":"Kontush","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2021.154887_bb0870","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1194\/jlr.P035808","article-title":"Plasma lipid profiling in a large population-based cohort","volume":"54","author":"Weir","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154887_bb0875","doi-asserted-by":"crossref","first-page":"14200","DOI":"10.1038\/s41598-018-31865-w","article-title":"Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome","volume":"8","author":"Lovric","year":"2018","journal-title":"Sci Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:28:49Z","timestamp":1758428929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":176,"alternative-id":["S0026049521001876"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154887","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unravelling lipoprotein metabolism with stable isotopes: tracing the flow","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154887"}}